




FIG. 1A




FIG. 1B




FIG. 2




FIG. 3




FIG. 4A




FIG. 4B




FIG. 5




FIG. 6

Biotin-mAB002(1.25ug/ml) /purified mAB(20ug/ml)




FIG. 7A

Biotin-mAB002(1.25ug/ml) /purified mAB(20ug/ml)




FIG. 7B




FIG. 8A




FIG. 8B




FIG. 8C




FIG. 9A




FIG. 9B




FIG. 9C

Humanized-54 antibodies binding to hVEGFR2-his




FIG. 10A

Humanized-48 antibodies binding to hVEGFR2-his




FIG. 10B




FIG. 11A




FIG. 11B




FIG. 12




FIG. 13A




FIG. 13B




FIG. 14A




FIG. 14B




FIG. 14C




FIG. 15





FIG. 17


HL-60 engraftment on NOD/SCID mice



1.5×10⁷ HL-60 cell/mouse were injected intravenously.
3 days after inoculation mice wre intravenouslytreated saline, 1121B, 54-C and 2-C twice/week for 4 weeks.

FIG. 18

ELISA blocking assay was conducted to confirm its VEGF blockade activity.



	Chimeric-DC101(lot-1)	Chimeric-DC101(lot-2)	Chimeric-DC101(lot-3)
EC50	0.0645	0.04767	0.07641

FIG. 19

Blockade of mouse VEGFR2 binding to human VEGF165




FIG. 20

MKN45 xenograft tumor on nude mice (mean±S.E.M., n=10)




FIG. 21

H460 xenograft tumor on nude mice (mean±S.E.M., n=10)




FIG. 22

H1975 xenograft tumor on nude mice (mean±S.E.M., n=10)




FIG. 23